ACET

Adicet Bio, Inc. Common Stock (ACET) | Rumor.io

Adicet Bio

ACET

Attention (50-day avg)0%

Attention rank (50-day avg)#1,653

Bullish sentiment (50-day avg)66%

Price to earnings ratio-0.37

Market capitalization59.4M

Earnings per share-10.4

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-116.8M

Social

What share of all stock conversation is about ACET?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% +0	0% 0

Sep 28

Adicet Bio's (ACET) stock is down despite positive data from the Prula-cel (formerly ADI-001) study in patients with systemic lupus erythematosus with or without lupus nephritis.
Analysts are optimistic about ACET's prospects, with Jefferies setting a $19 price target and Wedbush raising its price target to $28.
The Prula-cel study showed high remission rates and favorable safety, with 50% of evaluable lupus nephritis patients achieving a complete renal response and 54% achieving DORIS remission at the 12-month mark.

Generated by AI

Sentiment

Of the messages about ACET that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% +27.19	64.71% -35.29	61.9% -24.46	73.31% -15.23
Bearish	33.33% -27.19	35.29% +35.29	38.1% +24.46	26.69% +15.23

Bullish· Oct 7

Adicet Bio's $ACET has announced an $80M direct offering to strengthen its cash runway, which is expected to attract buyers and drive the stock's upward momentum.
The company's positive ADI-001 data and financing announcement have set a target range of $1.10 - $1.40, with a projected gain of 13% - 28%.
Adicet Bio's allogeneic gamma delta T-cell therapies have shown promise, with analysts seeing upside and price targets near $5.50, making it an attractive investment opportunity.

Bearish· Oct 7

The company's management has made questionable decisions, including diluting the stock immediately and stunting the company's progress by another 6 months.
The offering participants and bookrunners are weak, making it a dead stock with easy short opportunities.
The stock has failed to gain traction, with no buyers in the open market and no interest in purchasing at the $1 price, leading to a continued decline in price.

Generated by AI

Topics

Of the messages about ACET that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	66.67%	86.84%	92%	86.71%
Technical Analysis	0%	0%	0%	3.96%
Analysts	33.33%	13.16%	8%	8.39%
Controversies	0%	0%	0%	0.16%
Earnings	0%	0%	0%	0.79%
Macro	0%	0%	0%	0%

Earnings· Feb 1

Adicet Bio, Inc. ($ACET) missed EPS estimates by $0.01 and revenue estimates.
The company reported FQ2 earnings of 22c EPS and $171.23M in revenue.
Adicet Bio, Inc. ($ACET) sees FY18 EPS of $1.00-1.05, a decrease from previous estimates of $1.05-1.15.

Announcements· Oct 7

Adicet Bio announces $80 million registered direct offering of common stock at $1 per share.
The company also received FDA clearance for IND application for ADI-270 in renal cell carcinoma and is advancing allogeneic gamma delta T-cell therapies.
Analysts see upside potential in Adicet Bio with price targets near $5.50, driven by positive clinical data and a potentially transformational approach to treating autoimmune diseases.

Technical Analysis· Dec 6

$ACET is experiencing a strong shorting sentiment, with some traders expecting a price drop, particularly if it fails to hold above key support levels.
The stock has formed a cup and handle pattern, which could be a bullish signal, but some traders are cautious due to the presence of a head and shoulders pattern and a potential bull trap.
$ACET is currently finding support at certain levels, but some traders are concerned about its ability to regain a previous low and stay above the VWAP, which could be a key test of its strength.

Generated by AI

Community

Of the messages about ACET, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	35.29%	64.77%	79.29%	25.02%
Newcomers	64.71%	35.23%	20.71%	74.98%

Regulars· Oct 7

Adicet Bio has announced a positive preliminary data from its ADI-001 Phase 1 study in patients with lupus nephritis and systemic lupus erythematosus, with all patients showing sustained improvement without any safety concerns.
The company has priced its $80 million registered direct offering at $1 per share, which is below the deal price, indicating a potential inefficiency in the market.
The regulars are excited about the potential cure for diabetes and lupus, and are stepping in to support the scientists behind the ADI-001 treatment.

Newcomers· Sep 28

Adicet Bio's Prula-cel shows promising Phase 1 data for lupus treatment, with high remission rates and favorable safety.
The company announces positive safety and efficacy data from the Prula-cel study in patients with Systemic Lupus Erythematosus with or without Lupus Nephritis.
The 12-month mark data shows 50% of evaluable lupus nephritis patients achieved a complete renal response (CRR) and 54% of evaluable patients achieved DORIS remission.

Generated by AI

Adicet Bio (NASDAQ:ACET) reported 12-month DORIS remission in 54% of evaluable systemic lupus erythematosus patients and complete renal response in 50% of evaluable lupus nephritis patients, supporting plans to begin pivotal study start-up activities in the fourth quarter of 2026. Key Investor TakeawaysAdicet Bio (NASDAQ:ACET) reported positive prula-cel Phase 1 lupus data from 22 efficacy-evaluable patients, including 16 with lupus nephritis and six with extra-renal SLE.

1d agoYahoo Finance

Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients

1d agoYahoo Finance

Adicet Bio reports lupus trial results, plans pivotal study

2d agoInvesting.com

Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

26d agoYahoo Finance

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.

26d agoYahoo Finance

Also Discussed

Investors talking about ACET also mention

#	Name	Attention
1	PMV Pharmaceuticals, Inc.PMVP	0%0
2	Century Therapeutics IncIPSC	0%0
3	PSTX - Poseida Therapeutics, Inc.	——
4	Biodexa Pharmaceuticals plc ADRBDRX	0%+0
5	Alpha Metallurgical Resources, Inc.AMR	0%0
6	Legacy Education Inc.LGCY	0%new
7	Bio-Path Holdings Inc.BPTH	0%0
8	Immunic, Inc.IMUX	0%0
9	Highway Holdings LimitedHIHO	0%0
10	Lyell Immunopharma, Inc.LYEL	0.01%new

Adicet Bio, Inc. Common Stock

Healthcare
Biotechnology

Adicet Bio, Inc. Common Stock is the equity of Adicet Bio, a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s current pipeline centers on engineered, off-the-shelf cell therapies designed to target specific disease markers through chimeric antigen receptors, with lead programs such as prulacabtagene leucel and ADI-212 addressing autoimmune and oncology indications. Adicet Bio’s research and development efforts are aimed at advancing differentiated cell therapy candidates that combine immune-cell engineering with tumor-targeting or disease-modifying mechanisms. The company operates within the biotechnology and health technology sectors, where its programs contribute to the broader development of next-generation immunotherapies for patients with serious and difficult-to-treat conditions. Adicet Bio is headquartered in Boston, Massachusetts.

Website

Location

131 Dartmouth Street

Boston, MA, 02116

United States

Social

What share of all stock conversation is about ACET?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% +0	0% 0

Sep 28

Adicet Bio's (ACET) stock is down despite positive data from the Prula-cel (formerly ADI-001) study in patients with systemic lupus erythematosus with or without lupus nephritis.
Analysts are optimistic about ACET's prospects, with Jefferies setting a $19 price target and Wedbush raising its price target to $28.
The Prula-cel study showed high remission rates and favorable safety, with 50% of evaluable lupus nephritis patients achieving a complete renal response and 54% achieving DORIS remission at the 12-month mark.

Generated by AI

Sentiment

Of the messages about ACET that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% +27.19	64.71% -35.29	61.9% -24.46	73.31% -15.23
Bearish	33.33% -27.19	35.29% +35.29	38.1% +24.46	26.69% +15.23

Bullish· Oct 7

Adicet Bio's $ACET has announced an $80M direct offering to strengthen its cash runway, which is expected to attract buyers and drive the stock's upward momentum.
The company's positive ADI-001 data and financing announcement have set a target range of $1.10 - $1.40, with a projected gain of 13% - 28%.
Adicet Bio's allogeneic gamma delta T-cell therapies have shown promise, with analysts seeing upside and price targets near $5.50, making it an attractive investment opportunity.

Bearish· Oct 7

The company's management has made questionable decisions, including diluting the stock immediately and stunting the company's progress by another 6 months.
The offering participants and bookrunners are weak, making it a dead stock with easy short opportunities.
The stock has failed to gain traction, with no buyers in the open market and no interest in purchasing at the $1 price, leading to a continued decline in price.

Generated by AI

Topics

Of the messages about ACET that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	66.67%	86.84%	92%	86.71%
Technical Analysis	0%	0%	0%	3.96%
Analysts	33.33%	13.16%	8%	8.39%
Controversies	0%	0%	0%	0.16%
Earnings	0%	0%	0%	0.79%
Macro	0%	0%	0%	0%

Earnings· Feb 1

Adicet Bio, Inc. ($ACET) missed EPS estimates by $0.01 and revenue estimates.
The company reported FQ2 earnings of 22c EPS and $171.23M in revenue.
Adicet Bio, Inc. ($ACET) sees FY18 EPS of $1.00-1.05, a decrease from previous estimates of $1.05-1.15.

Announcements· Oct 7

Adicet Bio announces $80 million registered direct offering of common stock at $1 per share.
The company also received FDA clearance for IND application for ADI-270 in renal cell carcinoma and is advancing allogeneic gamma delta T-cell therapies.
Analysts see upside potential in Adicet Bio with price targets near $5.50, driven by positive clinical data and a potentially transformational approach to treating autoimmune diseases.

Technical Analysis· Dec 6

$ACET is experiencing a strong shorting sentiment, with some traders expecting a price drop, particularly if it fails to hold above key support levels.
The stock has formed a cup and handle pattern, which could be a bullish signal, but some traders are cautious due to the presence of a head and shoulders pattern and a potential bull trap.
$ACET is currently finding support at certain levels, but some traders are concerned about its ability to regain a previous low and stay above the VWAP, which could be a key test of its strength.

Generated by AI

Community

Of the messages about ACET, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	35.29%	64.77%	79.29%	25.02%
Newcomers	64.71%	35.23%	20.71%	74.98%

Regulars· Oct 7

Adicet Bio has announced a positive preliminary data from its ADI-001 Phase 1 study in patients with lupus nephritis and systemic lupus erythematosus, with all patients showing sustained improvement without any safety concerns.
The company has priced its $80 million registered direct offering at $1 per share, which is below the deal price, indicating a potential inefficiency in the market.
The regulars are excited about the potential cure for diabetes and lupus, and are stepping in to support the scientists behind the ADI-001 treatment.

Newcomers· Sep 28

Adicet Bio's Prula-cel shows promising Phase 1 data for lupus treatment, with high remission rates and favorable safety.
The company announces positive safety and efficacy data from the Prula-cel study in patients with Systemic Lupus Erythematosus with or without Lupus Nephritis.
The 12-month mark data shows 50% of evaluable lupus nephritis patients achieved a complete renal response (CRR) and 54% of evaluable patients achieved DORIS remission.

Generated by AI

Adicet Bio

Social

Sep 28

Bullish· Oct 7

Bearish· Oct 7

Earnings· Feb 1

Announcements· Oct 7

Technical Analysis· Dec 6

Regulars· Oct 7

Newcomers· Sep 28

Wedbush raises Adicet Bio stock price target on lupus trial data

Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance

Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients

Adicet Bio reports lupus trial results, plans pivotal study

Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

Also Discussed

Adicet Bio, Inc. Common Stock

Company Information

Location

Wedbush raises Adicet Bio stock price target on lupus trial data

Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance

Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients

Adicet Bio reports lupus trial results, plans pivotal study

Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

Also Discussed

Social

Sep 28

Bullish· Oct 7

Bearish· Oct 7

Earnings· Feb 1

Announcements· Oct 7

Technical Analysis· Dec 6

Regulars· Oct 7

Newcomers· Sep 28